1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Drugs In Development, 2022, provides an overview of the Rosacea (Dermatology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 11 and 13 respectively.
Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Rosacea - Overview
- Rosacea - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Rosacea - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rosacea - Companies Involved in Therapeutics Development
- Rosacea - Drug Profiles
- Rosacea - Dormant Projects
- Rosacea - Discontinued Products
- Rosacea - Product Development Milestones
- Featured News & Press Releases
- Jun 13, 2022: Dermata announces final patient enrolled in a phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea
- Mar 17, 2022: Journey Medical Corporation announces first patient dosed in phase 3 clinical trial evaluating DFD-29 (minocycline modified release capsules 40 mg) for the treatment of rosacea
- Nov 17, 2021: Dermata announces first patient enrolled in its phase 2 trial of DMT310 for the treatment of moderate-to-severe rosacea
- Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
- Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea
- May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea
- Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea
- Oct 12, 2018: BioPharmX enrols first subject in Phase llb trial of BPX-04
- Aug 01, 2018: BioPharmX secures IRB approval to start Phase ll trial of BPX-04
- May 24, 2018: BioPharmX Studies Show Hydrophilic Topical Minocycline Gel May Be the Preferred Treatment Option for Rosacea Patients
- Mar 20, 2018: U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug BPX-04
- Jan 26, 2018: BioPharmX To Present Data On New Fluorescence Lifetime Imaging Microscopy to Measure How Effectively Topically Applied Minocycline Reaches Targets in Skin
- Jan 12, 2018: BioPharmX to Present BPX-04 Rosacea Data at Two Leading Clinical Conferences This Month
- Dec 13, 2017: Hovione Announces Enrollment of First Patient in MARS, a Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
- Sep 12, 2017: BioPharmX Announces Preliminary Data from Rosacea Feasibility Study
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Rosacea, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Rosacea - Pipeline by Accuitis Pharmaceuticals Inc, 2022
- Rosacea - Pipeline by Alfasigma SpA, 2022
- Rosacea - Pipeline by Amgen Inc, 2022
- Rosacea - Pipeline by Amytrx Therapeutics Inc, 2022
- Rosacea - Pipeline by AOBiome LLC, 2022
- Rosacea - Pipeline by Arcutis Biotherapeutics Inc, 2022
- Rosacea - Pipeline by Attillaps Holdings Inc, 2022
- Rosacea - Pipeline by Biomimetix JV LLC, 2022
- Rosacea - Pipeline by Botanix Pharmaceuticals Ltd, 2022
- Rosacea - Pipeline by Cellix Bio Pvt Ltd, 2022
- Rosacea - Pipeline by Dermata Therapeutics Inc, 2022
- Rosacea - Pipeline by Evommune Inc, 2022
- Rosacea - Pipeline by Hovione FarmaCiencia SA, 2022
- Rosacea - Pipeline by Maruho Co Ltd, 2022
- Rosacea - Pipeline by Matrisys Bioscience Inc, 2022
- Rosacea - Pipeline by NanoPharmaceuticals LLC, 2022
- Rosacea - Pipeline by Perpetuum BV, 2022
- Rosacea - Pipeline by Promius Pharma LLC, 2022
- Rosacea - Pipeline by Retinoids JSC, 2022
- Rosacea - Pipeline by Sunny Pharmtech Inc, 2022
- Rosacea - Pipeline by Tarsus Pharmaceuticals Inc, 2022
- Rosacea - Pipeline by Timber Pharmaceuticals Inc, 2022
- Rosacea - Pipeline by TWi Biotechnology Inc, 2022
- Rosacea - Pipeline by VYNE Therapeutics Inc, 2022
- Rosacea - Dormant Projects, 2022
- Rosacea - Dormant Projects, 2022 (Contd..1)
- Rosacea - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Rosacea, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Accuitis Pharmaceuticals Inc
- Alfasigma SpA
- Amgen Inc
- Amytrx Therapeutics Inc
- AOBiome LLC
- Arcutis Biotherapeutics Inc
- Attillaps Holdings Inc
- Biomimetix JV LLC
- Botanix Pharmaceuticals Ltd
- Cellix Bio Pvt Ltd
- Dermata Therapeutics Inc
- Evommune Inc
- Hovione FarmaCiencia SA
- Maruho Co Ltd
- Matrisys Bioscience Inc
- NanoPharmaceuticals LLC
- Perpetuum BV
- Promius Pharma LLC
- Retinoids JSC
- Sunny Pharmtech Inc
- Tarsus Pharmaceuticals Inc
- Timber Pharmaceuticals Inc
- TWi Biotechnology Inc
- VYNE Therapeutics Inc
